FDA rejects Disc's rare disease drug despite commissioner's voucher Read more 

'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments Read more 

After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio Read more 

About Charles Muriuki

This author has not yet filled in any details.
So far Charles Muriuki has created 2 blog entries.
Go to Top